These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 26124485)

  • 1. Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group.
    Hofheinz RD; Gencer D; Schulz H; Stahl M; Hegewisch-Becker S; Loeffler LM; Kronawitter U; Bolz G; Potenberg J; Tauchert F; Al-Batran SE; Schneeweiss A
    J Clin Oncol; 2015 Aug; 33(22):2444-9. PubMed ID: 26124485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome.
    Iwase S; Ishiki H; Watanabe A; Shimada N; Chiba T; Kinkawa J; Tojo A
    J Clin Oncol; 2016 Feb; 34(4):391. PubMed ID: 26628471
    [No Abstract]   [Full Text] [Related]  

  • 3. Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5.
    Wolf SL; Qin R; Menon SP; Rowland KM; Thomas S; Delaune R; Christian D; Pajon ER; Satele DV; Berenberg JL; Loprinzi CL;
    J Clin Oncol; 2010 Dec; 28(35):5182-7. PubMed ID: 21060036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Randomized Single-Blinded Phase II Trial Comparing Efficacy and Quality of Life of Topical Aloe Vera Gel Plus Urea Cream Versus Urea Cream Alone for Prevention of Hand Foot Syndrome in Cancer Patients Receiving Capecitabine.
    Wanichtanom L; Vrakornvoravuti G; Boonsiri M; Suthepwanon A
    Asian Pac J Cancer Prev; 2024 Jun; 25(6):2203-2210. PubMed ID: 38918684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study.
    Kang YK; Lee SS; Yoon DH; Lee SY; Chun YJ; Kim MS; Ryu MH; Chang HM; Lee JL; Kim TW
    J Clin Oncol; 2010 Aug; 28(24):3824-9. PubMed ID: 20625131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reply to S. Iwase et al.
    Hofheinz RD; Burkholder I; Schneeweiss A
    J Clin Oncol; 2016 Feb; 34(4):392. PubMed ID: 26628462
    [No Abstract]   [Full Text] [Related]  

  • 7. [Assessment of hand-foot syndrome in cancer patients treated with capecitabine-containing chemotherapy].
    Yamagiwa K; Shigematsu T; Takeda K; Shirai M; Amemori K; Sunda K; Koike C; Yamada T
    Gan To Kagaku Ryoho; 2013 Dec; 40 Suppl 2():161-3. PubMed ID: 24712132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Effect of Pyridoxine for Prevention of Hand-Foot Syndrome in Colorectal Cancer Patients with Adjuvant Chemotherapy Using Capecitabine: A Randomized Study.
    Ota M; Tatsumi K; Suwa H; Watanabe J; Watanabe K; Osada S; Tanaka K; Shoichi F; Ichikawa Y; Kunisaki C; Endo I
    Hepatogastroenterology; 2014 Jun; 61(132):1008-13. PubMed ID: 26158157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial.
    Zhang RX; Wu XJ; Wan DS; Lu ZH; Kong LH; Pan ZZ; Chen G
    Ann Oncol; 2012 May; 23(5):1348-1353. PubMed ID: 21940785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer.
    Yoshimoto N; Yamashita T; Fujita T; Hayashi H; Tsunoda N; Kimura M; Tsuzuki N; Yamashita H; Toyama T; Kondo N; Iwata H
    Breast Cancer; 2010 Oct; 17(4):298-302. PubMed ID: 19789949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Curcuma longa (Turmeric) for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Pilot Study.
    Scontre VA; Martins JC; de Melo Sette CV; Mutti H; Cubero D; Fonseca F; Del Giglio A
    J Diet Suppl; 2018 Sep; 15(5):606-612. PubMed ID: 29095653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of life under capecitabine (Xeloda®) in patients with metastatic breast cancer: data from a german non-interventional surveillance study.
    Müller V; Fuxius S; Steffens CC; Lerchenmüller C; Luhn B; Vehling-Kaiser U; Hurst U; Hahn LJ; Soeling U; Wohlfarth T; Zaiss M
    Oncol Res Treat; 2014; 37(12):748-55. PubMed ID: 25531721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Breast cancer and the hand-foot syndrome].
    Llambrich C; Falcou MC; De Rycke Y; Cottu P; Carrié S; Medjbari M
    Soins; 2012 Jun; (766):25-8. PubMed ID: 22870762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significant association between hand-foot syndrome and efficacy of capecitabine in patients with metastatic breast cancer.
    Azuma Y; Hata K; Sai K; Udagawa R; Hirakawa A; Tohkin M; Ryushima Y; Makino Y; Yokote N; Morikawa N; Fujiwara Y; Saito Y; Yamamoto H
    Biol Pharm Bull; 2012; 35(5):717-24. PubMed ID: 22687407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy of AboundTM for hand-foot syndrome caused by capecitabine].
    Fujii C; Imamura H; Fukunaga M; Kamigaki S; Kimura Y; Kawase T; Kawabata R; Fujino M; Iseki C; Hamaguchi Y; Yamamoto E; Ishizaka T; Hachino Y
    Gan To Kagaku Ryoho; 2013 Nov; 40(12):2457-9. PubMed ID: 24394143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Oral capecitabine as postoperative adjuvant chemotherapy in stage III colon cancer patients].
    Yamaguchi T; Fukuda M; Yasui H; Okazaki S; Kubo K; Tanaka M; Une Y; Setoguchi Y; Hanada K; Moriyama S; Tani M; Murakami T; Okuchi Y; Ogiso S; Hata H; Sakata S; Otani T; Yamato T; Ikai I
    Gan To Kagaku Ryoho; 2012 Mar; 39(3):389-93. PubMed ID: 22421765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial.
    Yap YS; Kwok LL; Syn N; Chay WY; Chia JWK; Tham CK; Wong NS; Lo SK; Dent RA; Tan S; Mok ZY; Koh KX; Toh HC; Koo WH; Loh M; Ng RCH; Choo SP; Soong RCT
    JAMA Oncol; 2017 Nov; 3(11):1538-1545. PubMed ID: 28715540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial.
    Santhosh A; Sharma A; Bakhshi S; Kumar A; Sharma V; Malik PS; Pramanik R; Gogia A; Prasad CP; Sehgal T; Gund S; Dev A; Cheung WY; Pandey RM; Kumar S; Gupta I; Batra A;
    J Clin Oncol; 2024 May; 42(15):1821-1829. PubMed ID: 38412399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer.
    Blum JL; Barrios CH; Feldman N; Verma S; McKenna EF; Lee LF; Scotto N; Gralow J
    Breast Cancer Res Treat; 2012 Dec; 136(3):777-88. PubMed ID: 23104222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of hand-foot syndrome in patients treated with capecitabine (Xeloda).
    Lassere Y; Hoff P
    Eur J Oncol Nurs; 2004; 8 Suppl 1():S31-40. PubMed ID: 15341880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.